The short half-life of endogenous GLP-1 has led to the development of GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors as therapeutic strategies to extend the duration of GLP-1 action in the treatment of type 2 diabetes (17). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.